https://www.taxtmi.com/news?id=61248 A Phase III non inferiority trial in 240 chemotherapy patients found OERISTM (extended release ondansetron injection) achieved a higher complete response rate (89% vs. 82%) and showed comparable or improved tolerability with no serious adverse events; the sponsor plans regulatory filings and global registration using established pathways for reformulated products. en-us Tue, 11 Nov 2025 13:01:03 +0530 Tue, 11 Nov 2025 13:01:04 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=61248 A Phase III non inferiority trial in 240 chemotherapy patients found OERISTM (extended release ondansetron injection) achieved a higher complete response rate (89% vs. 82%) and showed comparable or improved tolerability with no serious adverse events; the sponsor plans regulatory filings and global registration using established pathways for reformulated products. News - Tue, 11 Nov 2025 13:01:03 +0530 https://www.taxtmi.com/news?id=61248